Pure Bioscience Enhances Board With Food Safety Expert
PURE Bioscience Appoints Darin Zehr to Board of Directors
PURE Bioscience, Inc. ((
PURE Bioscience GAAP EPS of -$0.01, Revenue of $0.33M
PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
Update on Business and PURE's SDC-Based Antimicrobial Food Safety SolutionsEL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patent
Pure Bioscience 2Q Loss/Shr 1c >PURE
Pure Bioscience 2Q Loss/Shr 1c >PURE
PURE Bioscience GAAP EPS of -$0.01, Revenue of $0.72M
PURE Bioscience Reports Fiscal First Quarter 2024 Financial Results
Update on Business and PURE's SDC-Based Antimicrobial Food Safety SolutionsEL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patent
Pure Bioscience 1Q Loss/Shr 1c >PURE
Pure Bioscience 1Q Loss/Shr 1c >PURE
PURE Bioscience GAAP EPS of -$0.04, Revenue of $1.87M
PURE Bioscience Reports Fiscal 2023 Financial Results
Update on Business and PURE's SDC-Based Antimicrobial Food Safety SolutionsEL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patent
PURE Bioscience to Unveil "PURE Genius" Food Safety Program at the Annual International Association for Food Protection Meeting
July 16th-19th, 2023, Toronto, Ontario, Canada Booth #530RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SD
PURE Bioscience Q3 EPS $(0.01), Same YoY, Sales $406.00K
PURE Bioscience Q3 EPS $(0.01), Same YoY, Sales $406.00K
Pure Bioscience 3Q Loss/Shr 1c >PURE
Pure Bioscience 3Q Loss/Shr 1c >PURE
PURE Bioscience Reports Fiscal 2023 Third Quarter And Nine-Month Financial Results
Update on Business Segments and PURE's SDC-Based Antimicrobial SolutionsRANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydro
Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Declines By 14.7%
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,400 shares, a decrease of 14.7%
PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 14.7% in April
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 6,400 shares, a drop of 14.7
PURE Bioscience (OTCMKTS:PURE) Stock Price Passes Above 200 Day Moving Average of $0.15
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.15 and traded as high as $0.1
PURE Bioscience GAAP EPS of -$0.01, Revenue of $0.4M
PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results
RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for th
Pure Bioscience 2Q Loss $1.06M >PURE
Pure Bioscience 2Q Loss $1.06M >PURE
No Data